|
At
June 30, 2021, there were the following potentially dilutive securities that were excluded from diluted net loss per share because their
effect would be anti-dilutive (all shares adjusted to reflect a 25:1 reverse stock split effected on September 4, 2020):
SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE
| Shares from the conversion of Series
B Preferred Stock |
|
|
15,625,000 |
|
| Shares from the conversion of Series E-1 Preferred
Stock (subject to vesting in 2021 through 2023 and potential forfeiture) |
|
|
8,500,000 |
|
| Shares from common stock options |
|
|
468,619 |
|
| Shares from common stock warrants |
|
|
7,493,575 |
|
| Shares from the conversion of debentures |
|
|
218,750 |
|
| Shares from the conversion of redeemable convertible
preferred stock (based upon an assumed conversion price at June 30, 2021 of $0.16 per share; not inclusive of cumulative dividends
which may be converted to shares of common stock under certain conditions) |
|
|
3,000,000 |
|
At
June 30, 2020, there were the following potentially dilutive securities that were excluded from diluted net loss per share because their
effect would be anti-dilutive (all shares adjusted to reflect a 25:1 reverse stock split effected on September 4, 2020):
| Shares from common stock options |
|
|
468,619 |
|
| Shares from common stock warrants |
|
|
46,154 |
|
| Shares from the conversion of debentures |
|
|
66,000 |
|
| Shares that may be converted from Bridge Notes
(based upon an assumed conversion price at June 30, 2020 of $1.98 per share); |
|
|
2,087,234 |
|
| Shares from the conversion of redeemable convertible
preferred stock (not inclusive of cumulative dividends which may be converted to shares of common stock under certain conditions). |
|
|
302,768 |
|
|